AABB 2011 Annual Meeting, October 22- 25, San Diego

Thank you for joining us at AABB.

We have posted the pdfs below for the posters presented at the event and will also be uploading the video of the workshop shortly. 

See you next year in Boston!

Symposium

View the webinar replay

Presented Tuesday Oct 25 - 7:00am - 8:15am

TITLE:
Pathogen inactivation from the patient's viewpoint: assessing current risks and benefits of blood transfusion

DESCRIPTION:
Blood component risks are typically calculated on a per-unit basis, but patients receive varying numbers of transfusions throughout their therapies and face different risks depending on the frequency and geography in which they are transfused. This Workshop will explore emerging pathogen risks from the perspective of a multiply-transfused patient, including a review of the European experience with platelets and plasma treated with the INTERCEPT pathogen inactivation system.
 

SPEAKERS :
Lyle R. Petersen, MD, MPH Director, Division of Vector-Borne Diseases Centers for Disease Control and Prevention
Steven Kleinman, MD, Clinical Professor of Pathology University of British Columbia School of Medicine President, Kleinman Biomedical Research
Behrouz Mansouri Taleghani, MD Associate Professor, Inselspital Bern Medical Director, Blood Transfusion Service, Swiss Red Cross, Bern

Poster Presentations

INTERCEPT data for platelets, plasma, and red blood cells will be featured in five posters at the AABB Annual Meeting in San Diego. We welcome you to stop by the poster luncheon starting at noon on Saturday October 22 to speak with the authors and learn more about their studies.

INTERCEPT Blood System for Platelets

Assessment of Hemostatis in Platelet Transfusion Clinical Trials with Differential Follow-up.
Sherman C, Reed W, Corash L. 
[Poster PDF]

Influence on HLA alloimmunisation frequency in hematology patients supported with INTERCEPT pathogen inactivated (PI) platelet components (PC).
Osselaer JC, Vandendaele MC, Guldenpfenning M, et al.
[Poster PDF]

INTERCEPT Blood System for Plasma

Characteristics of Liquid Plasma treated with the INTERCEPT Blood System for Pathogen Inactivation and Stored at 4°C for 14 days
Knutson F, Loef H, Pinkoski L, et al.
[Poster PDF]

Methicillin Resistance Does Not Impact Inactivation of Staphylococcus aureus by Amotosalen and UVA Illumination.
Hanson D, Arnold D, Sawyer L.
[Poster PDF]

INTERCEPT Blood System for Red Blood Cells

Process Robustness of the S-303 Pathogen Inactivation System for Red Blood Cells.
Erickson A, Hanson D, Donnelly B, et al.
[Poster PDF]

Cerus Booth

Check back for booth photos from the event!